Table 5.
Proportion of people with T2DM (n=58 717) prescribed medications in the past 1, 3 and 10 years prior to 31 July 2015
| Medication | Prescribed in past 1 year n (%) | Prescribed in past 3 years n (%) | Prescribed in past 10 years n (%) |
|---|---|---|---|
| Metformin | 37 045 (63.1) | 39 872 (67.9) | 43 179 (73.5) |
| Thiazolidinediones | 1826 (3.1) | 2642 (4.5) | 5989 (10.2) |
| Sulfonylureas | 15 547 (26.5) | 17 696 (30.1) | 20 819 (35.5) |
| Meglitinides | 174 (0.3) | 257 (0.4) | 541 (0.9) |
| DPP-4 inhibitors | 6941 (11.8) | 8462 (14.4) | 9453 (16.1) |
| α-glucosidase inhibitors | 98 (0.2) | 146 (0.2) | 295 (0.5) |
| SGLT2 inhibitors | 1267 (2.2) | 1267 (2.2) | 1267 (2.2) |
| GLP1 analogues | 1930 (3.3) | 2497 (4.3) | 2842 (4.8) |
| Insulin | 8403 (14.3) | 8806 (15.0) | 9442 (16.1) |
DPP-4, dipeptidase IV; GLP1, glucagon-like peptide 1; SGLT2, sodium glucose co-transporter 2; T2DM, type 2 diabetes mellitus.